Adaptimmune Therapeutics Net Worth
Adaptimmune Therapeutics Net Worth Breakdown | ADAP |
Adaptimmune Therapeutics Net Worth Analysis
Adaptimmune Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Adaptimmune Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Adaptimmune Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Adaptimmune Therapeutics' net worth analysis. One common approach is to calculate Adaptimmune Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Adaptimmune Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Adaptimmune Therapeutics' net worth. This approach calculates the present value of Adaptimmune Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Adaptimmune Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Adaptimmune Therapeutics' net worth. This involves comparing Adaptimmune Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Adaptimmune Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Adaptimmune Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adaptimmune Therapeutics' net worth research are outlined below:
| Adaptimmune Therapeutics generated a negative expected return over the last 90 days | |
| Adaptimmune Therapeutics has some characteristics of a very speculative penny stock | |
| Adaptimmune Therapeutics has high historical volatility and very poor performance | |
| Adaptimmune Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 60.28 M. Net Loss for the year was (113.87 M) with loss before overhead, payroll, taxes, and interest of (100.58 M). | |
| Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (140.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Europes TCR immunotherapy licensing deals surge 123 percent above US in 2024 |
Adaptimmune Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adaptimmune Therapeutics Plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adaptimmune Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Adaptimmune Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adaptimmune Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptimmune Therapeutics Plc backward and forwards among themselves. Adaptimmune Therapeutics' institutional investor refers to the entity that pools money to purchase Adaptimmune Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 1.7 M | Jpmorgan Chase & Co | 2024-06-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 881.7 K | Millennium Management Llc | 2024-06-30 | 779.6 K | Redmile Group, Llc | 2024-09-30 | 715.6 K | Rathbone Brothers Plc | 2024-06-30 | 432.8 K | State Street Corp | 2024-06-30 | 390.9 K | Dafna Capital Management Llc | 2024-09-30 | 341.1 K | Key Client Fiduciary Advisors, Llc | 2024-09-30 | 255.4 K | Matrix Capital Management Company, Llc | 2024-06-30 | 39 M | Ecor1 Capital, Llc | 2024-09-30 | 27.4 M |
Follow Adaptimmune Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 169.29 M.Market Cap |
|
Project Adaptimmune Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (2.88) | (2.74) |
When accessing Adaptimmune Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Adaptimmune Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adaptimmune Therapeutics' profitability and make more informed investment decisions.
Evaluate Adaptimmune Therapeutics' management efficiency
Adaptimmune Therapeutics has return on total asset (ROA) of (0.1584) % which means that it has lost $0.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.42. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 11/25/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.20 | 0.19 | |
| Tangible Book Value Per Share | 0.19 | 0.19 | |
| Enterprise Value Over EBITDA | (0.32) | (0.33) | |
| Price Book Value Ratio | 4.04 | 4.24 | |
| Enterprise Value Multiple | (0.32) | (0.33) | |
| Price Fair Value | 4.04 | 4.24 | |
| Enterprise Value | 40.7 M | 38.7 M |
Evaluating the management effectiveness of Adaptimmune Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Adaptimmune Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 0.3296 | Revenue 141.5 M | Quarterly Revenue Growth 23.996 | Revenue Per Share 0.595 | Return On Equity (0.65) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptimmune Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptimmune Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptimmune Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adaptimmune Therapeutics time-series forecasting models is one of many Adaptimmune Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adaptimmune Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Adaptimmune Therapeutics Earnings per Share Projection vs Actual
Adaptimmune Therapeutics Corporate Management
| Kerry Sharp | Senior Council | Profile | |
| Dennis Williams | Senior Development | Profile | |
| Sbastien Desprez | VP Affairs | Profile | |
| Dana Lynch | Senior Communications | Profile | |
| Helen MBA | CoFounder Officer | Profile | |
| Bertrand Esq | Chief Officer | Profile |
Already Invested in Adaptimmune Therapeutics Plc?
The danger of trading Adaptimmune Therapeutics Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptimmune Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptimmune Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptimmune Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.